Cosentyx Patient Assistance Program (2026)

The following medications are covered by Cosentyx Connect (via Novartis):

Cosentyx (secukinumab) is an IL-17A inhibitor manufactured by Novartis that carries a retail price of $5,000 or more per month, translating to over $60,000 per year. The drug is FDA-approved for multiple autoimmune and inflammatory conditions: moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and enthesitis-related arthritis. This range of indications makes Cosentyx relevant to both dermatologists and rheumatologists, and the Cosentyx Connect program is structured to support patients across all approved uses through a single enrollment process.

The Novartis Patient Assistance Foundation provides free Cosentyx to uninsured patients with household income up to 500% of the Federal Poverty Level, which is approximately $75,300 for a single individual. This is notably higher than many competing biologic PAPs that cap at 400% FPL, giving more middle-income patients a pathway to free medication. For commercially insured patients, the Cosentyx Connect savings card can reduce copays to $0 per fill for eligible patients. The savings card carries a maximum annual benefit, so patients with very high commercial copays should verify that the card covers their full annual costs. Novartis also offers a separate $0 copay bridge program for patients waiting on insurance prior authorization decisions, ensuring no gaps in treatment.

Cosentyx Connect includes practical support beyond just financial assistance. The program offers one-on-one injection training, where a nurse demonstrates how to use the Sensoready autoinjector pen or the prefilled syringe. Patients can choose their preferred injection device, and the program ships medication directly to the patient's home via specialty pharmacy. Cosentyx must be stored refrigerated (36 to 46 degrees Fahrenheit) and brought to room temperature for 15 to 30 minutes before injection. For the psoriasis loading dose (five weekly injections followed by monthly maintenance), the program coordinates shipping to ensure you receive enough medication for the initial phase. Renewal requires resubmitting income documentation annually. If you are switching from another biologic (such as Humira or Taltz), ask your dermatologist to coordinate the overlap period with Cosentyx Connect so there is no break in assistance coverage.

1. Speak with your healthcare provider about Cosentyx Connect (via Novartis). Your doctor, nurse, or social worker can help determine if you qualify.
2. Gather required documents: proof of income (tax return, pay stubs, or Social Security statement), valid prescription, and proof of U.S. residency.
3. Submit your application online or by mail. Visit the program website below or call the program hotline for assistance.
4. Wait for approval (typically 2 to 6 weeks). Once approved, medications will be shipped to your provider's office or a designated pharmacy.